Stockscreener 앱 받기
18.69
6.69%
-1.34
시간 외 거래:
18.69
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Major Cancer Drug Breakthrough: Enliven Unveils Triple-Asset Data at AACR 2025 - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.9% After Insider Selling - Defense World
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock By Investing.com - Investing.com Australia
Enliven Therapeutics CFO Benjamin Hohl sells $69,320 in stock - Investing.com India
Where are the Opportunities in (ELVN) - news.stocktradersdaily.com
Swiss National Bank Increases Stock Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO sells $22,504 in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CFO sells $22,504 in stock - Investing.com India
Charles Schwab Investment Management Inc. Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Bank of New York Mellon Corp Sells 828 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics chief scientific officer sells $257,575 in stock By Investing.com - Investing.com Canada
Enliven Therapeutics chief scientific officer sells $257,575 in stock - Investing.com India
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory - Marketscreener.com
(ELVN) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Lifesci Capital Issues Optimistic Forecast for ELVN Earnings - Defense World
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock - Investing.com
Enliven Therapeutics CEO Samuel Kintz sells $260,320 in stock By Investing.com - Investing.com UK
Decoding Enliven Therapeutics Inc (ELVN): A Strategic SWOT Insig - GuruFocus.com
Enliven grew fourth-quarter R&D spending with trials underway - BizWest
Enliven Therapeutics Stock (ELVN): Promising Advances in Oncology Pipeline - Value The Markets
Enliven Therapeutics Reports 2024 Financial Results - TipRanks
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update - Citizentribune
Enliven Therapeutics Inc. (ELVN) reports earnings - Quartz
Enliven Therapeutics Q4 Operating Expenses USD 26.896 Million -March 13, 2025 at 05:37 pm EDT - Marketscreener.com
ENLIVEN THERAPEUTICS Earnings Results: $ELVN Reports Quarterly Earnings - Nasdaq
Enliven Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (ELVN) Enliven Therapeutics Posts Q4 Loss $-0.46 Per Share -March 13, 2025 at 04:12 pm EDT - Marketscreener.com
Enliven Therapeutics Secures 3-Year Runway with $313M War Chest, Advances Cancer Drug Pipeline - Stock Titan
Enliven Therapeutics COO Anish Patel sells $142,936 in stock - Investing.com
Enliven Therapeutics COO Anish Patel sells $142,936 in stock By Investing.com - Investing.com Australia
(ELVN) Investment Analysis and Advice - Stock Traders Daily
Enliven Therapeutics (ELVN) Projected to Post Quarterly Earnings on Thursday - Defense World
New York State Common Retirement Fund Sells 2,488 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics CFO Sells Shares - TradingView
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - Longview News-Journal
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap DownHere's Why - MarketBeat
(ELVN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $146,207.31 in Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock - MSN
Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat
Enliven Therapeutics COO Anish Patel sells $146,205 in stock By Investing.com - Investing.com South Africa
Trend Tracker for (ELVN) - Stock Traders Daily
10.70%
자본화:
|
볼륨(24시간):